Klivira
Request demo

Optimizing Hospitalist Biologics Prior Auth Workflows

Hospitalists frequently encounter complex biologics prior auth requirements, impacting patient care continuity and timely discharge. Klivira provides a clear path to automate these critical workflows.

For revenue cycle directors and prior authorization coordinators, managing specialty drug PAs in an inpatient setting presents unique challenges. High-cost biologics, often initiated or continued during hospitalization, demand precise and efficient prior authorization to prevent care delays and financial write-offs. Klivira’s platform addresses the specific needs of hospitalist biologics prior auth.

The Hospitalist's Role in Biologics Management and PA Burden

While often initiated in outpatient settings, biologics such as TNF inhibitors, IL-17/23 inhibitors, and JAK inhibitors are critical for patients admitted for exacerbations of chronic conditions like IBD, rheumatoid arthritis, or severe asthma. Hospitalists are responsible for ensuring continuity of these high-cost therapies, managing re-authorizations during extended stays, and coordinating access upon discharge. The manual burden of biologics prior authorization can significantly impact discharge planning and length of stay.

Navigating Biologics Prior Authorization for Inpatient Care

The intersection of hospitalist care and biologics PA involves specific triggers: managing existing biologic therapies during admission, initiating biologics for acute indications, or facilitating re-authorization cycles that fall within an inpatient stay. These scenarios require navigating complex indication-specific PA criteria, step therapy requirements, and biosimilar substitution policies, often under time constraints that are incompatible with manual processes. The CAQH Index highlights the substantial volume of specialty pharmacy PA, where biologics represent a meaningful share.

Key Elements of Klivira's Biologics PA Automation for Hospitalists

  • **Indication Classification:** Identifies specialty and disease state from EMR diagnoses to align with payer PA criteria.
  • **Step Therapy Automation:** Pulls prior-line therapy history (e.g., csDMARDs, 5-ASA) to satisfy step therapy requirements.
  • **Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates to ensure compliance and cost-efficiency.
  • **Screening Documentation:** Automates retrieval of TB (PPD or IGRA), hepatitis B/C, and immunization status from FHIR data.
  • **Periodic Re-authorization:** Manages typical 6/12-month cycles with continuous disease-activity and response documentation.
  • **Medical-vs-Pharmacy Benefit Routing:** Differentiates benefit-side routing for agents depending on administration mode.

Integrating Biologics PA with Hospitalist EMR Workflows

Klivira integrates directly with major EMR systems using SMART on FHIR, allowing hospitalists and their teams to initiate and manage biologics prior authorizations without leaving their native EMR environment. This includes capturing relevant clinical documentation, ordering information, and patient demographics directly from the EMR. Payer communication occurs via X12 278, ePA portals, and NCPDP SCRIPT, minimizing manual data entry and portal hopping for hospital staff.

Ensuring Continuity and Compliance with Biologics PA

Automating hospitalist biologics prior auth not only accelerates patient care but also bolsters compliance. Klivira's logic aligns with clinical guideline bodies relevant to biologics (e.g., NCCN, ACR, AGA, AAD, ATS) to ensure medical necessity is consistently met. By proactively managing re-authorizations and documenting required screenings, the platform helps prevent denials and supports seamless transitions of care from inpatient to outpatient settings, ensuring patients maintain access to their critical therapies.

Frequently asked questions

How does Klivira handle emergency biologics prior authorizations for hospitalists?

Klivira's platform is designed to expedite the PA process by automating data extraction and submission. For true emergencies, our system can flag urgent requests and route them through the fastest available payer channels (e.g., real-time ePA, expedited fax) while ensuring all necessary clinical documentation is attached.

Can Klivira integrate with our existing EMR for biologics orders?

Yes, Klivira offers robust integration with leading EMR systems via SMART on FHIR. This allows hospitalists to initiate biologics prior authorizations directly from their EMR, pulling patient data and order details automatically, streamlining the workflow and reducing manual effort.

What types of biologics does Klivira's PA automation cover?

Klivira's platform covers a broad spectrum of biologics, including TNF inhibitors, IL-17/23 inhibitors, IL-6 inhibitors, and JAK inhibitors, across various specialties such as rheumatology, gastroenterology, dermatology, neurology, and pulmonology, which are commonly encountered in hospitalist patient populations.

How does Klivira manage periodic re-authorization for chronic biologic therapies during an inpatient stay?

Klivira's system tracks authorization expiration dates and proactively initiates re-authorization workflows. For patients on chronic biologics who are admitted, the platform can leverage inpatient documentation for disease activity and response, ensuring timely submission to payers and maintaining continuity of therapy.

Does Klivira assist with medical vs. pharmacy benefit routing for biologics?

Yes, Klivira's intelligent routing system can determine whether a specific biologic agent, depending on its administration mode (e.g., infusion vs. self-injection), falls under the medical or pharmacy benefit. This ensures the prior authorization request is sent to the correct payer channel, preventing delays and rework.

Related coverage

Other hospitalist prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo